CA3137672A1 - Process for the preparation of clc-1 chloride channel inhibitors - Google Patents
Process for the preparation of clc-1 chloride channel inhibitors Download PDFInfo
- Publication number
- CA3137672A1 CA3137672A1 CA3137672A CA3137672A CA3137672A1 CA 3137672 A1 CA3137672 A1 CA 3137672A1 CA 3137672 A CA3137672 A CA 3137672A CA 3137672 A CA3137672 A CA 3137672A CA 3137672 A1 CA3137672 A1 CA 3137672A1
- Authority
- CA
- Canada
- Prior art keywords
- phenoxy
- dihydroisoxazol
- bromo
- butoxy
- ethoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19181262 | 2019-06-19 | ||
| EP19181262.7 | 2019-06-19 | ||
| PCT/EP2020/067065 WO2020254554A1 (en) | 2019-06-19 | 2020-06-19 | Process for the preparation of clc-1 chloride channel inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3137672A1 true CA3137672A1 (en) | 2020-12-24 |
Family
ID=66999603
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3137672A Pending CA3137672A1 (en) | 2019-06-19 | 2020-06-19 | Process for the preparation of clc-1 chloride channel inhibitors |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US12221425B2 (https=) |
| EP (1) | EP3986878B1 (https=) |
| JP (1) | JP7595945B2 (https=) |
| KR (1) | KR102900834B1 (https=) |
| CN (1) | CN113993852B (https=) |
| AR (1) | AR119198A1 (https=) |
| AU (1) | AU2020298092B2 (https=) |
| BR (1) | BR112021025588A2 (https=) |
| CA (1) | CA3137672A1 (https=) |
| ES (1) | ES3000437T3 (https=) |
| HU (1) | HUE069104T2 (https=) |
| IL (1) | IL287901B2 (https=) |
| MX (1) | MX2021013507A (https=) |
| PL (1) | PL3986878T3 (https=) |
| SG (1) | SG11202111122RA (https=) |
| TW (1) | TWI849152B (https=) |
| WO (1) | WO2020254554A1 (https=) |
| ZA (1) | ZA202107653B (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4593829A1 (en) | 2022-09-30 | 2025-08-06 | NMD Pharma A/S | Compositions and methods for treating myasthenia gravis |
| WO2024180199A1 (en) | 2023-03-02 | 2024-09-06 | Nmd Pharma A/S | Compositions and methods for treating charcot–marie–tooth disease |
| JP2026508357A (ja) | 2023-03-02 | 2026-03-10 | エヌエムディー ファーマ エー／エス | 脊髄性筋萎縮症を処置するための組成物及び方法 |
| EP4731200A1 (en) | 2023-06-20 | 2026-04-29 | NMD Pharma A/S | Clc-1 inhibitors for use in the treatment of multiple sclerosis and neuromuscular diseases |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0301010D0 (sv) * | 2003-04-07 | 2003-04-07 | Astrazeneca Ab | Novel compounds |
| GB0422057D0 (en) * | 2004-10-05 | 2004-11-03 | Astrazeneca Ab | Novel compounds |
| GB0524428D0 (en) * | 2005-11-30 | 2006-01-11 | 7Tm Pharma As | Medicinal use of receptor ligands |
| WO2009097970A1 (de) * | 2008-02-05 | 2009-08-13 | Sanofi-Aventis | Triazolopyridazine als par1-inhibitoren, ihre herstellung und verwendung als arzneimittel |
| JP2015505560A (ja) * | 2012-02-03 | 2015-02-23 | ゾエティス・エルエルシー | 抗寄生虫薬としてのキラルイソオキサゾリンアゼチジン誘導体の製造法 |
| MX389242B (es) | 2015-06-15 | 2025-03-20 | Nmd Pharma As | Compuestos para su uso en el tratamiento de trastornos neuromusculares |
| US10385028B2 (en) * | 2017-12-14 | 2019-08-20 | Nmd Pharma A/S | Compounds for the treatment of neuromuscular disorders |
| TWI780281B (zh) | 2017-12-14 | 2022-10-11 | 丹麥商Ｎｍｄ藥品公司 | 用於治療神經肌肉病症的化合物 |
-
2020
- 2020-06-19 BR BR112021025588A patent/BR112021025588A2/pt unknown
- 2020-06-19 IL IL287901A patent/IL287901B2/en unknown
- 2020-06-19 ES ES20734157T patent/ES3000437T3/es active Active
- 2020-06-19 SG SG11202111122RA patent/SG11202111122RA/en unknown
- 2020-06-19 EP EP20734157.9A patent/EP3986878B1/en active Active
- 2020-06-19 CN CN202080043796.2A patent/CN113993852B/zh active Active
- 2020-06-19 HU HUE20734157A patent/HUE069104T2/hu unknown
- 2020-06-19 TW TW109120910A patent/TWI849152B/zh active
- 2020-06-19 US US17/619,312 patent/US12221425B2/en active Active
- 2020-06-19 JP JP2021569300A patent/JP7595945B2/ja active Active
- 2020-06-19 MX MX2021013507A patent/MX2021013507A/es unknown
- 2020-06-19 CA CA3137672A patent/CA3137672A1/en active Pending
- 2020-06-19 AR ARP200101735A patent/AR119198A1/es unknown
- 2020-06-19 AU AU2020298092A patent/AU2020298092B2/en active Active
- 2020-06-19 KR KR1020217037880A patent/KR102900834B1/ko active Active
- 2020-06-19 WO PCT/EP2020/067065 patent/WO2020254554A1/en not_active Ceased
- 2020-06-19 PL PL20734157.9T patent/PL3986878T3/pl unknown
-
2021
- 2021-10-11 ZA ZA2021/07653A patent/ZA202107653B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3986878A1 (en) | 2022-04-27 |
| HUE069104T2 (hu) | 2025-02-28 |
| BR112021025588A2 (pt) | 2022-02-01 |
| IL287901A (en) | 2022-01-01 |
| PL3986878T3 (pl) | 2025-01-20 |
| EP3986878C0 (en) | 2024-09-25 |
| CN113993852A (zh) | 2022-01-28 |
| TWI849152B (zh) | 2024-07-21 |
| US12221425B2 (en) | 2025-02-11 |
| KR102900834B1 (ko) | 2025-12-16 |
| AU2020298092A1 (en) | 2021-11-18 |
| CN113993852B (zh) | 2024-12-17 |
| SG11202111122RA (en) | 2021-11-29 |
| MX2021013507A (es) | 2021-12-10 |
| TW202115003A (zh) | 2021-04-16 |
| AU2020298092A8 (en) | 2025-04-24 |
| IL287901B2 (en) | 2025-02-01 |
| WO2020254554A1 (en) | 2020-12-24 |
| ES3000437T3 (en) | 2025-02-28 |
| JP2022537493A (ja) | 2022-08-26 |
| JP7595945B2 (ja) | 2024-12-09 |
| IL287901B1 (en) | 2024-10-01 |
| AU2020298092B2 (en) | 2025-09-25 |
| ZA202107653B (en) | 2023-05-31 |
| EP3986878B1 (en) | 2024-09-25 |
| KR20220022895A (ko) | 2022-02-28 |
| AR119198A1 (es) | 2021-12-01 |
| US20220298124A1 (en) | 2022-09-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3986878B1 (en) | Process for the preparation of clc-1 chloride channel inhibitors | |
| TWI345562B (en) | Rosuvastatin and salts thereof free of rosuvastatin alkylether and a process for the preparation thereof | |
| Shi et al. | Syntheses and insecticidal activities of novel 2-fluorophenyl-5-aryl/cyclopropyl-1, 3, 4-oxadiazoles | |
| Erhardt et al. | Conformational analogs of dopamine. Synthesis and pharmacological activity of (E)-and (Z)-2-(3, 4-dihydroxyphenyl) cyclopropylamine hydrochlorides | |
| EP3237379B1 (en) | Process for preparing alpha-carboxamide pyrrolidine derivatives | |
| JP6693520B2 (ja) | ピペラジン誘導体 | |
| HK40068865A (en) | Process for the preparation of clc-1 chloride channel inhibitors | |
| HK40068865B (en) | Process for the preparation of clc-1 chloride channel inhibitors | |
| JP7662196B2 (ja) | 神経筋障害の治療のための化合物 | |
| Tatum et al. | Synthesis, Ni (II) Schiff base complexation and structural analysis of fluorinated analogs of the ligand (S)-2-[N-(N′-benzylprolyl) amino] benzophenone (BPB) | |
| GB2124621A (en) | New isocarbostryl-3-carboxylic acid derivatives and the preparation thereof | |
| US11578081B1 (en) | Crystal form as inhibitor of ACC1 and ACC2, and preparation method therefor and use thereof | |
| EP3939976B1 (en) | Prodrug of caspase inhibitor | |
| Kolasa et al. | Esters of N‐Benzyloxyamino Acids | |
| WO2018033631A9 (en) | Morphic forms of marizomib and uses thereof | |
| KR100758317B1 (ko) | 몰폴린-2-온 유도체를 포함하는 ｔ-형 칼슘 채널 차단용조성물 | |
| WO2026057052A1 (zh) | 一种il-23受体抑制剂及其制备方法和用途 | |
| JP2022551769A (ja) | チエノ［２，３－ｃ］ピリダジン－４（１Ｈ）－オン系化合物の結晶形及びその製造方法並びに使用 | |
| EP2529738A1 (en) | Substituted terpyridines | |
| JP2017141185A (ja) | プロレニン受容体リガンド及びアンタゴニスト | |
| HK1198476A1 (zh) | 咪唑啉类衍生物、其制备方法及其在医药上的应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20240613 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250521 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250521 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D149 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S INTERVIEW Effective date: 20250605 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20250613 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250616 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250730 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250730 |
|
| D22 | Grant of ip right intended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT Effective date: 20251209 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20251216 |